PMID: 9315992Oct 8, 1997Paper

Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders

Journal of Clinical Psychopharmacology
P V TranG D Tollefson

Abstract

Olanzapine and risperidone, both second-generation antipsychotic agents, represent two different pharmacologic strategies. Although they share some in vitro properties, they differ by virtue of their chemical structure, spectrum of receptor binding affinities, animal neuropharmacology, pharmacokinetics, and in vivo neuroimaging profile. Based on such differences, it was hypothesized that the two compounds would show distinct safety and/or efficacy characteristics. To test this hypothesis, an international, multicenter, double-blind, parallel-group, 28-week prospective study was conducted with 339 patients who met DSM-IV criteria for schizophrenia, schizophreniform disorder, or schizoaffective disorder. Results of the study indicated that both olanzapine and risperidone were safe and effective in the management of psychotic symptoms. However, olanzapine demonstrated significantly greater efficacy in negative symptoms (Scale for Assessment of Negative Symptoms summary score), as well as overall response rate (> or = 40% decrease in the Positive and Negative Syndrome Scale total score). Furthermore, a statistically significantly greater proportion of the olanzapine-treated than risperidone-treated patients maintained their respons...Continue Reading

References

Apr 1, 1977·The Journal of Nervous and Mental Disease·C P Miles
Jan 1, 1991·Schizophrenia Bulletin·H Y Meltzer
May 1, 1989·The British Journal of Psychiatry : the Journal of Mental Science·T R Barnes
Mar 1, 1989·Archives of General Psychiatry·R T Segraves
Jan 1, 1987·Schizophrenia Bulletin·S R KayL A Opler
Jan 1, 1970·Acta Psychiatrica Scandinavica. Supplementum·G M Simpson, J W Angus
Apr 1, 1982·Archives of General Psychiatry·G F JohnsonJ M Rey
Aug 1, 1982·The Journal of Nervous and Mental Disease·A M GhadirianL Annable
Jan 1, 1984·Schizophrenia Bulletin·D W HeinrichsW T Carpenter
Jan 4, 1996·The New England Journal of Medicine·J M Kane
Jun 1, 1994·The American Journal of Psychiatry·S R Marder, R C Meibach
Jan 1, 1994·Comprehensive Psychiatry·D D MillerN C Andreasen
Feb 1, 1996·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·F P BymasterD T Wong
Feb 1, 1996·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·G S Robertson, H C Fibiger
Feb 1, 1996·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·C M BeasleyS Hamilton
Mar 1, 1996·Psychopharmacology·B J Kinon, J A Lieberman
Mar 1, 1996·Psychopharmacology·C M BeasleyS Hamilton
Jun 1, 1997·Journal of Clinical Psychopharmacology·G M Simpson, J P Lindenmayer
Nov 14, 1997·The American Journal of Psychiatry·W S Fenton, T H McGlashan

❮ Previous
Next ❯

Citations

Aug 10, 2006·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Stephen M BeardEckart Rüther
Feb 26, 2013·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·S LeuchtR R Engel
Sep 15, 2004·European Psychiatry : the Journal of the Association of European Psychiatrists·Antonio CiudadUNKNOWN EFESO Study Group
Dec 4, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Frank P BymasterDavid L Mckinzie
Jan 31, 2004·Progress in Neuro-psychopharmacology & Biological Psychiatry·Martin R K DossenbachUNKNOWN Olanzapine HGCH Study Group
Jan 31, 2004·Progress in Neuro-psychopharmacology & Biological Psychiatry·Takefumi SuzukiHaruo Kashima
Apr 20, 2004·Progress in Neuro-psychopharmacology & Biological Psychiatry·Claire AdvokatJoseph E Comaty
Aug 14, 2003·Biological Psychiatry·Steven G PotkinUNKNOWN InterSePT Study Group
Dec 1, 1999·Biological Psychiatry·J M Kane
Oct 30, 1998·Journal of Psychiatric Research·M D Jibson, R Tandon
Oct 30, 1998·Journal of Psychiatric Research·J R DeQuardo, R Tandon
Jan 11, 2001·Physiology & Behavior·P F Frohlich, C M Meston
Aug 2, 2002·Pharmacology, Biochemistry, and Behavior·Jun-ichi KarasawaKazutoshi Horikomi
Jan 1, 2003·Journal of Affective Disorders·Robert W BakerMauricio Tohen
Dec 31, 2002·Archives of Medical Research·Murad AtmacaOmer Gecici
Dec 31, 2002·Archives of Medical Research·Cynthia S PalmerDennis A Revicki
Nov 28, 2002·Progress in Neuro-psychopharmacology & Biological Psychiatry·Thomas L SchwartzPrakash S Masand
Jun 6, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·José Manuel MontesUNKNOWN EFESO Study Group
Dec 23, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Frank-Gerald Pajonk
Jan 13, 2000·Progress in Neuro-psychopharmacology & Biological Psychiatry·H RosengartenA J Friedhoff
Dec 31, 2002·Psychoneuroendocrinology·R Tandon, M D Jibson
Dec 31, 2002·Psychoneuroendocrinology·A J Cutler
Oct 25, 2001·Journal of Clinical Epidemiology·J A SacristánP Kind
Dec 20, 2000·Schizophrenia Research·J RabinowitzZ Kaplan
Nov 5, 2002·Schizophrenia Research·Herbert Y MeltzerKaruna Jayathilake
Feb 20, 2003·Schizophrenia Research·Teresa J HudsonCarol R Thrush
May 27, 2003·Schizophrenia Research·S Charles SchulzMartin Brecher
Apr 6, 1999·Schizophrenia Research·R G Petty
Apr 6, 1999·Schizophrenia Research·R A Dickson, W M Glazer
Apr 6, 1999·Schizophrenia Research·D E Casey
Apr 6, 1999·Schizophrenia Research·J H KrystalI L Petrakis
Apr 6, 1999·Schizophrenia Research·G D Tollefson, T M Sanger
Oct 14, 2000·European Psychiatry : the Journal of the Association of European Psychiatrists·P CarrièreT Lempérière
Aug 21, 2003·European Psychiatry : the Journal of the Association of European Psychiatrists·Ann M Mortimer
Nov 26, 1999·European Psychiatry : the Journal of the Association of European Psychiatrists·R BenatovZ Zemishlany
Feb 23, 2000·European Psychiatry : the Journal of the Association of European Psychiatrists·E StipP Liddle
Oct 6, 2001·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·S KasperA Heiden
Dec 14, 2002·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Enrique AlvarezUNKNOWN EUROPA Study Group

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Related Papers

The Journal of Clinical Psychiatry
Chittaranjan Andrade
CNS Drugs
Juliane Weber, Paul L McCormack
Drug Design, Development and Therapy
Maria Rosaria A MuscatelloRocco Zoccali
© 2021 Meta ULC. All rights reserved